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Abstract
Autoimmune hemolytic anemia (AIHA) is a disease process that involves the destruction of red blood cells mediated by
the humoral immune system. It can be characterized as a cold agglutinin syndrome, paroxysmal cold hemoglobinuria, and
warm, mixed type, and drug-induced AIHA. Although a well-established relationship exists between the presence of AIHA
and lymphoproliferative malignancy, AIHA rarely presents in association with solid malignancies. An analysis of the limited
number of published cases of AIHA in association with solid malignancies performed showed that AIHA may present before
the diagnosis of a solid malignancy, concurrently with the presence of a solid malignancy, or even on resolution of a solid
malignancy. Few cases of solid cancers associated with AIHA have been reported. AIHA rarely presents as a paraneoplastic
syndrome indicating existence of a solid cancer. We report a case of inflammatory breast cancer with AIHA.
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Introduction
The association between autoimmune hemolytic anemia
(AIHA) and lymphoproliferative disorders is well-established.1-3 However, significantly fewer cases of AIHA have
been reported in malignant solid cancers,4 with a notably rare
occurrence in breast malignancy. To diagnose AIHA in the
setting of a solid tumor, a solid tumor must be present and the
diagnosis of AIHA must be made using both direct and indirect Coombs tests and presence of anti-erythrocyte antibodies. In a 2016 Bulgarian study that focused on assessing the
incidence of autoimmune disorders and solid tumors, out of
the 1083 patients with solid tumors that were studied, only
1.29% of the solid tumors were associated with autoimmune
paraneoplastic syndromes. Of the solid tumors that also had
autoimmune paraneoplastic syndromes, 14% were associated
with AIHA, and these were related to either a solid tumor of
the prostate or of the ovary with none associated with a solid
breast malignancy. AIHA is also found in renal cell carcinoma
and Kaposi sarcoma. Idiopathic autoimmune disorders differ
from autoimmune paraneoplastic phenomenon by the timing
of the development of the disorder as autoimmune paraneoplastic phenomena develop either at the same time as the primary tumor or following the development of the tumor.5

There are 2 reported cases in the literature that show an associated malignant mesothelioma solid tumor with AIHA.6
There are only a few reported cases of malignant solid breast
cancer with AIHA.7,8 In a study of 160 patients with both
erythrocyte autoantibodies and cancer, a P value of <.0005
was found for a single patient to have both erythrocyte autoantibodies and cancer, suggesting that the existence of the 2
conditions within one patient is statistically significant and
tends to occur more often with metastatic cancers, large
tumors, and is indicative of a poor prognosis. A total of 12.5%
of the patients with both erythrocyte autoantibodies and cancer had breast cancer as their primary tumor, and 7.5% of
these patients had warm autoantibody AIHA and breast cancer, similar to the patient presented in this case report.9 The
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Figure 1. PET-CT at diagnosis and following 6 cycles of chemotherapy. Left column: PET-CT at diagnosis prior to chemotherapy. Right
column: PET-CT following 6 cycles of chemotherapy.

existence of additional cases of AIHA and breast cancer suggests that there is possibly an association between solid breast
malignancy and AIHA. Temporal associations observed in
some cases suggest a potential role of AIHA as an indicator of
disease remission, progression, or recurrence.
We report a rare case of AIHA in inflammatory breast
cancer.

Case Presentation
The patient is a 40-year-old Caucasian female who presented
with a 2-week history of nonproductive cough, generalized
weakness, dyspnea, and subjective fever. Examination
revealed a large mass in the left breast with near-complete
replacement of the breast tissue. There was associated erythema, induration, and skin ulceration with bilateral palpable
axillary lymphadenopathy. Complete blood count with differential revealed the following: white blood cell count 7500/µL,
hemoglobin 4.0 g/dL, hematocrit 13.4%, platelets 119 000/µL,
43% segmented neutrophils, 22% lymphocytes, 8% monocytes, 2% basophils, and 23% metamyelocytes. Additional
workup revealed a haptoglobin level <10 mg/dL, a lactate
dehydrogenase level of 1282 U/L, a reticulocyte count >19%,
and an immunoglobulin G (IgG) positive direct Coombs test,
suggesting AIHA. Based on these findings, the patient received
multiple transfusions of packed red blood cells in addition to
methylprednisolone for her hemolytic anemia.

Chest computed tomography (CT) scan showed left
breast enlargement, left pleural effusion, and diffuse lymphadenopathy. Breast biopsy showed invasive carcinoma with
involvement of the overlying skin and lymphatic system.
Immunohistochemical analysis showed that the tumor was
estrogen receptor positive and progesterone receptor negative. Fluorescence in situ hybridization (FISH) evaluation
was positive for HER2 gene expression. Positron-emission
tomography (PET) scan showed hepatosplenomegaly, a left
breast mass measuring 10 cm × 9 cm × 5 cm, bilateral axillary lymphadenopathy, and a hypermetabolic 6.6 cm diameter pelvic mass. The patient was diagnosed with stage IV
invasive ductal carcinoma. She received palliative chemotherapy consisting of docetaxel, transtuzumab, and pertuzumab. Repeat PET-CT scan following 6 cycles of
chemotherapy showed improvement in the breast mass and
lymphadenopathy, as seen in Figure 1.
However, there was progression of metastatic breast cancer involving the sternum and parasternal soft tissues; multiple cervical thoracic, portacaval, and pelvic nodal
metastases; and extensive left side pleural metastases. The
abdominal mass pathological result reported the abdominal
mass diagnosis as leiomyoma. It lacked atypia and had
extremely low mitotic rate, which is as compatible with a
benign process. Notably, with response to chemotherapy,
there was a decrease in hemolytic activity, and the patient
was weaned off steroids. There was a subsequent increase in
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hemolytic activity after cycle 6 of chemotherapy, however,
possibly correlating with progression of metastatic breast
cancer.

Investigations
Evaluation of inflammatory breast cancer and warm antibody hemolytic anemia (AIHA) includes collection of
images, laboratory studies of blood samples, and histopathological sampling of tissue. Dynamic contrast-enhanced magnetic resonance imaging provides the ability to assess
multicentric and/or multifocal disease along with skin
involvement, whereas mammography has shown limited
sensitivity. PET is being used for staging and for detecting
early metastatic disease.10 For our patient, we diagnosed
using CT scan, PET scan, immunohistochemical analysis,
and FISH evaluation. Blood work includes complete blood
count, reticulocyte count, lactate dehydrogenase, haptoglobin, and Coombs test. Breast tissue biopsy provides the
definitive diagnosis.

Treatment
Treatment of the AIHA depends on the characteristics of
the concurrent solid tumor. For this patient’s breast cancer,
which was estrogen receptor positive, progesterone receptor negative, and positive for HER2 gene expression,
docetaxel, transtuzumab, and pertuzumab were initiated.
AIHA improved with chemotherapy treatment of the breast
solid tumor, suggesting that the solid breast tumor was the
underlying etiology of the AIHA. Recurrence of the AIHA
following 6 cycles of chemotherapy in a patient with progression of metastatic breast cancer suggests that the recurrent AIHA may be secondary to the progression of the
metastatic breast cancer that has become unresponsive to
the chemotherapy.

Discussion
This is a rare case of infiltrative inflammatory breast cancer
with a solid mass presenting with concurrent warm antibody
AIHA. Mechanisms underlying associations between solid
tumors and AIHA remain unclear. However, correlation of
hemolytic activity with disease progression or recurrence
might be potentially useful in monitoring disease. Further
study of patients with breast cancer and AIHA will provide
more information on underlying etiology mechanisms.
Inflammatory breast cancer has a very poor prognosis.
Molecular subtyping has limited predicted and prognostic
value. Triple-negative inflammatory breast cancer is strongly
associated with a poor prognosis compared with other subtypes of inflammatory breast cancer, which include hormonal
receptor and HER2-defined subtypes. Currently available
treatments are unlikely to improve the outcomes. A HER2positive status does not necessarily indicate a good prognosis

as targeted therapies are not effective in terms of improving
outcomes.11
Inflammatory breast cancer has been reported as a very
aggressive form of breast cancers. This was seen in our
patient despite prompt treatment and initial partial response
to chemotherapy; the metastases at other sites continue to
progress despite the comprehensive multidisciplinary
approach to the management of this disease, so the prognosis
remains dismal.12
Chemotherapy that is used to treat the solid tumor will
cause the secondary AIHA to respond with a decrease in
hemolytic activity as well if AIHA is due to the solid tumor.
A response in the AIHA following chemotherapy initiation
suggests that the solid tumor is also responding to the chemotherapy. The AIHA initially responded following initiation of chemotherapy, suggesting initial response of the
breast tumor to the chemotherapy. AIHA returned with an
increase in hemolytic activity as the breast cancer progressed
and metastasized further.

Conclusion
If treatment of the solid tumor with chemotherapy resulted in
improvement of the AIHA, then it is highly likely that the
AIHA was secondary to the solid tumor. The AIHA level can
be used to determine the responsiveness of the tumor to the
chemotherapy.13 AIHA is a rare paraneoplastic syndrome
that has been reported in very few cases to be associated with
ovarian cancer, lung, stomach, and breast cancers. Some of
the cases reported occurred after or during treatment with
carboplatin. Our patient was not on any treatment prior to her
presentation. Her presenting symptom was symptomatic
anemia. Workup for the anemia confirmed hemolytic anemia. Biomedical research is needed to understand the pathophysiology of AIHA in inflammatory breast cancer and its
potential role as a tool in the monitoring of response of
inflammatory breast cancer to chemotherapy treatment.
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